Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Januar 2022

Genmab — Januar 2022

Planlagt Fastgjort Låst Flyttet Genmab
1.2k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • nohopeN Offline
    nohopeN Offline
    nohope
    wrote on sidst redigeret af
    #52

    Deler din ærgelse over både GEN og Novo, ufatteligt at Novo er nede med over 4 % i dag.

    1 Reply Last reply
    0
    • StockBullS Offline
      StockBullS Offline
      StockBull
      wrote on sidst redigeret af
      #53

      Trendkanalen er intakt. Ser ud til vi er igang med en normal mini retracement. Vi har et meget interessandt mønster som måske skal gentages (3je gule streg med pil opad mod 3600). Ligner, at vi på ugekort går en længere opgangs periode i møde. Vi får se om dette set-up udspiller sig for i retning af det indikerede https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/99881_Skaermbillede_2022_01_04_170455_Gmab_4_januar.jpg

      1 Reply Last reply
      0
      • SolsenS Offline
        SolsenS Offline
        Solsen
        wrote on sidst redigeret af
        #54

        Tak for stregerne SB 🙂

        1 Reply Last reply
        0
        • V Offline
          V Offline
          Vitus
          wrote on sidst redigeret af
          #55

          Er det fortsat uden bankgaranti ? 🙂

          1 Reply Last reply
          0
          • V Offline
            V Offline
            Vitus
            wrote on sidst redigeret af
            #56

            Jeg vil så gerne tro på det…..og håber du får bare delvis ret.

            1 Reply Last reply
            0
            • V Offline
              V Offline
              Vitus
              wrote on sidst redigeret af
              #57

              Vi må håbe voldgiftssagen snart bliver afsluttet…

              1 Reply Last reply
              0
              • V Offline
                V Offline
                Vitus
                wrote on sidst redigeret af
                #58

                Og jeg beholder mine….jeg har jo læst Helges gode bog……

                1 Reply Last reply
                0
                • BulderB Offline
                  BulderB Offline
                  Bulder
                  wrote on sidst redigeret af
                  #59

                  Det gør den snart. Sidst i 21 eller lidt ind i 22 sagde Winkel på et tidspunkt. Med de fald vi har set, er et dårligt udfald sikkert allerede (delvist) indregnet.

                  1 Reply Last reply
                  0
                  • V Offline
                    V Offline
                    Vitus
                    wrote on sidst redigeret af
                    #60

                    Vi krydser alt hvad vi krydse kan Bulder..

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #61

                      Genmab A/S (GEN:DC) (GMAB) PT Raised to DKK3,200 at Bernstein https://www.avanza.se/placera/telegram/2022/01/04/genmab-bernstein-hojer-riktkursen-for-genmab-till-3-200-danska-kronor-3-150-upprepar-outperform-bn.html

                      1 Reply Last reply
                      0
                      • P Offline
                        P Offline
                        ProinvestorNEWS
                        wrote on sidst redigeret af
                        #62

                        Novo og sundhedsaktier ramt af genåbningshåb vurderer strateg https://www.proinvestor.com/investornyt/758638/novo-og-sundhedsaktier-ramt-af-genabningshab-vurderer-strateg

                        1 Reply Last reply
                        0
                        • SolsenS Offline
                          SolsenS Offline
                          Solsen
                          wrote on sidst redigeret af
                          #63

                          Genmab and Synaffix Enter into License Agreement for ADC Technology
                          Media Release

                          Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologies
                          Genmab secures rights for conducting research on ADCs against multiple drug targets with options for exclusive worldwide development and commercialization of resulting therapies
                          Synaffix to receive an upfront payment of USD $4.5 million with a total deal value of up to USD $415 million plus tiered single digit royalties on sales

                          1 Reply Last reply
                          0
                          • B Offline
                            B Offline
                            BioShare
                            wrote on sidst redigeret af
                            #64

                            Genmab og Synaffix indgår aftale om ADC.

                            1 Reply Last reply
                            0
                            • B Offline
                              B Offline
                              BioShare
                              wrote on sidst redigeret af
                              #65

                              https://ir.genmab.com/news-releases/news-release-details/genmab-and-synaffix-enter-license-agreement-adc-technology

                              1 Reply Last reply
                              0
                              • P Offline
                                P Offline
                                ProinvestorNEWS
                                wrote on sidst redigeret af
                                #66

                                Genmab and Synaffix Enter into License Agreement for ADC Technology https://www.proinvestor.com/investornyt/758658/genmab-and-synaffix-enter-into-license-agreement-for-adc-technology

                                1 Reply Last reply
                                0
                                • S Offline
                                  S Offline
                                  Sukkeralf
                                  wrote on sidst redigeret af
                                  #67

                                  site specific conjugation bl.a.

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #68

                                    bl.a. ?

                                    1 Reply Last reply
                                    0
                                    • M Offline
                                      M Offline
                                      Mcjean
                                      wrote on sidst redigeret af
                                      #69

                                      onder andere

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #70

                                        😉 ok

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #71

                                          it isn't that long ago that Jan told us how impressed he was with AbbVie ADC technology, calling it ADC 3.0 ... things change fast i guess

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper